pocketful logo light
pocketful logo light
Glenmark Pharmaceuticals Ltd logo

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK BSE: 532296

₹2209.60

(1.52%)

Wed, 17 Jun 2026, 07:28 pm

mtf coin illustrationMTF 5x

Glenmark Pharmaceuticals Share Price Live Chart

1 Day

(1.52%)

No Result Found

Summary

  • Market Cap (in Cr)

    64179.52

  • Net Profit (in Cr)

    1047.14

  • P/B

    4.91

  • Sector P/E

    33.76

  • P/E

    41.50

  • EV/EBITDA

    21.14

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    15.79

  • ROCE

    18.48

  • Debt/Equity

    0.22

  • EPS (TTM)

    95.92

  • Dividend Yield

    0.11

  • Book Value

    339.54

  • Interest Cover

    9.56

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (12.7x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (13.5x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Glenmark Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Glenmark Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Glenmark Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Glenmark Pharmaceuticals is expected to decrease over the next 2 years.
  • Glenmark Pharmaceuticals's earnings are expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
  • Glenmark Pharmaceuticals's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters46.6546.6546.6546.6546.65
FII20.3419.2020.7320.6223.16
DII19.2920.0918.6117.6414.60
Public13.6814.0213.9715.0615.56
Government0.040.040.040.040.04

Read More

Technical Analysis

RSI

38.78

MACD

-41.14

50 DMA

2267.37

200 DMA

2061.75

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2741.132527.432401.172313.732187.472100.031886.33
Fibonacci2527.432445.802395.372313.732232.102181.672100.03
Camarilla2333.672314.082294.492313.732255.312235.722216.13

Pivots Level: Classic

R3

+427.40

2741.13

R2

+213.70

2527.43

R1

+87.43

2401.17

2313.73
2313.73
Pivot Point
LTP: 2136.60

S1

-126.27

2187.47

S2

-213.70

2100.03

S3

-427.40

1886.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2172.69

  • 20-EMA

    2209.58

  • 30-EMA

    2227.31

  • 50-EMA

    2227.25

  • 100-EMA

    2176.56

  • 200-EMA

    2064.72

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts, Final Dividend
30 Jan 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
26 Sept 2025dividend₹2.50 Dividend /Share03 Oct 2025
03 Sept 2025dividendInterim Dividend - Rs. - 2.503 Oct 2025
22 Aug 2025agm
15 Aug 2025dividendFinal Dividend - Rs. - 2.515 Sept 2025
23 May 2025dividend₹2.50 Dividend /Share15 Sept 2025
30 Aug 2024agm
13 Aug 2024dividendDividend - Rs 2.50 Per Share17 Sept 2024

Read More

Peer Comparison

Glenmark Pharmaceuticals Ltd logo

Glenmark Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Glenmark Pharmaceuticals Ltd About

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1977

Headquarters

CEO

Glenn Saldanha

Employees

Contact

Website icon

Website

http://www.glenmarkpharma.com

Email icon

Email

complianceofficer@glenmarkpharma.com

Phone icon

Phone

91-22-40189999

Location icon

Location

B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Read More

Glenmark Pharmaceuticals Ltd Company History

YearHistory
2020
  • First to launch Remogliflozin + Vildagliptin FDC for Type 2 Diabetes in India.
  • Introduced NINDANIB (Nintedanib) for Pulmonary Fibrosis in India.
  • Introduced 400 mg strength FabiFlu for COVID-19 treatment.
  • Received USFDA approval for Deferasirox tablets for oral suspension.
  • Pledged 50 lakh meals amid COVID-19 pandemic.
  • Entered exclusive licensing agreement with Hikma for Ryaltris in US.
2021
  • Awarded International Safety Award.
  • Awarded Environmental, Social and Governance Summit & Awards.
  • Launched Rufinamide Tablets USP 200 mg and 400 mg.
  • Launched Ryaltris nasal spray in India.
2022
  • Received USFDA approval for Nicardipine Hydrochloride capsules.
  • Received ANDA approval for generic birth control drug.
  • Received India Pharma Innovation of the Year Award from Government of India.
  • First to launch Triple FDC Teneligliptin + Pioglitazone + Metformin for Type 2 Diabetes in India.
  • Launched Fingolimod Capsules 0.5 mg in US.
2023
  • Launched Bumetanide Injection USP 1 mg/4 mL and 2.5 mg/10 mL in US.
2024
  • Received US health regulator approval for generic stomach acid medication.
  • Launched Lacosamide Oral Solution 10 mg/mL in US.
  • Launched Travoprost Ophthalmic Solution USP 0.004% in US.
  • Received ANDA approval for Topiramate Capsules USP 15 mg and 25 mg.
  • Entered agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkSell15105912173.3111 Jul 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy15105912171.6711 Jul 2025
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.blockBuy2644651492.6525 Mar 2025
UBS AGblockSell2644651492.6525 Mar 2025
UBS PRINCIPAL CAPITAL ASIA LIMITEDblockSell671394151023 Jan 2025
UBS AGblockBuy671394151023 Jan 2025
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy39265397.925 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy302621397.925 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell302621397.925 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell39265397.925 Oct 2022

Read More

Glenmark Pharmaceuticals Ltd News

Glenmark Pharma Launches Winlevi® Cream Across Europe

Glenmark Pharmaceuticals launches Winlevi® Cream for acne treatment in major European markets, marking its first New Chemical Entity launch in Europe and expanding its dermatology portfolio.

11 Jun 2026

companies

Glenmark targets 13-15% revenue CAGR

Glenmark outlines strategy for FY26-30, focusing on branded growth and innovation to drive long-term value.

09 Jun 2026

companies

Glenmark launches Lacosamide Injection in US market

Glenmark Pharmaceuticals Inc. launched Lacosamide Injection USP in the US. The product is a therapeutic equivalent to UCB's Vimpat Injection.

05 Jun 2026

companies

Glenmark Pharma Eyes Respiratory Growth in FY27

Glenmark Pharmaceuticals targets respiratory product growth in FY27, with Winlevi® securing EU approval and Aumolertinib's initial launch anticipated in H2 FY27.

30 May 2026

companies

Glenmark appoints new Company Secretary

Glenmark Pharmaceuticals appointed Ms. Rashmi Khandelwal as Company Secretary & Compliance Officer effective May 30, 2026. Mr. Harish Kuber retired early from the role on May 29, 2026.

29 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number